Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 May 2022
SMC - May 2022 decisions
9 May 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 09 May 2022
Next Health Minister must restart the National Medicines Policy Review
10 May 2022 - Medicines Australia has released a video outlining the importance of restarting the National Medicines Policy Review ...
Posted by Michael Wonder on 09 May 2022
Product information update for COVID-19 treatment Xevudy (sotrovimab)
6 May 2022 - On 7 April 2022, the TGA announced receipt of an application from GSK for a higher (1000 ...
Posted by Michael Wonder on 09 May 2022
Choices that fail health and wellbeing
5 May 2022 - NICE's expert group RAPID C-19, set up to ‘to ensure safe and timely patient access to treatments ...
Posted by Michael Wonder on 08 May 2022
Wearable technology promises to revolutionise health care
5 May 2022 - Do not let bureaucracy delay matters. ...
Posted by Michael Wonder on 08 May 2022
NHS rolls out life-saving arthritis drug to treat COVID
5 May 2022 - The NHS is rolling out a cutting-edge, life-saving COVID treatment from today, which is proven to ...
Posted by Michael Wonder on 08 May 2022
Myovant & Pfizer provide update on supplemental new drug application for Myfembree for the management of moderate to severe pain associated with endometriosis
6 May 2022 - Myovant Sciences & Pfizer announced today that the U.S. FDA has extended the review period for the ...
Posted by Michael Wonder on 08 May 2022
Supporting innovation in Medicaid policy - interventions to increase adoption of RCTs
7 May 2022 - Randomised, controlled trials remain underutilised within the Medicaid program, even though state Medicaid programs regularly implement new ...
Posted by Michael Wonder on 07 May 2022
FDA limits use of Janssen COVID-19 vaccine to certain individuals
5 May 2022 - Today, the U.S. FDA has limited the authorised use of the Janssen COVID-19 Vaccine to individuals ...
Posted by Michael Wonder on 06 May 2022
Congress moves toward reforming FDA accelerated approvals, but with pharma friendly concessions
4 May 2022 - House lawmakers are moving a little closer toward cracking down on drugmakers that game the FDA’s ...
Posted by Michael Wonder on 06 May 2022
Patient reported outcome assessment must be inclusive and equitable
5 May 2022 - Patient reported outcomes are increasingly collected in clinical trials and in routine clinical practice, but strategies ...
Posted by Michael Wonder on 06 May 2022
Updated agenda for the July 2022 PBAC meeting
6 May 2022 - The agenda for the July 2022 PBAC meeting has been updated. ...
Posted by Michael Wonder on 05 May 2022
ICER to assess gene therapies for haemophilia A and B
5 May 2022 - Report will be subject of CTAF meeting in November 2022; draft scoping document open to public ...
Posted by Michael Wonder on 05 May 2022
ICER’s favourable assessment of Bluebird Bio’s gene therapy Zynteglo may have important pricing and reimbursement implications
5 May 2022 - ICER evaluated the clinical and cost-effectiveness - as well as budgetary impact - of one of two ...
Posted by Michael Wonder on 05 May 2022
Insights from the March 2022 PBAC meeting (part 4)
5 May 2022 - The apparent high recommendation rate for the March 2022 meeting does have some downsides. ...